Abstract:BACKGROUND:Gastric cancer (GC) represents a significant health burden with dire prognostic implications upon metastasis and recurrence. Pterostilbene (PTE) has been proven to have a strong ability to inhibit proliferation and metastasis in other cancers, while whether PTE exhibits anti-GC activity and its potential mechanism remain unclear.PURPOSE:To explore the efficacy and potential mechanism of PTE in treating GC.METHODS:We employed a comprehensive set of assays, including CCK-8, EdU staining, colony formation, flow cytometry, cell migration, and invasion assays, to detect the effect of PTE on the biological function of GC cells in vitro. The xenograft tumor model was established to evaluate the in vivo anti-GC activity of PTE. Network pharmacology was employed to predict PTE's potential targets and pathways within GC. Subsequently, Western blotting, immunofluorescence, and immunohistochemistry were utilized to analyze protein levels related to the cell cycle, EMT, and the JAK2/STAT3 pathway.RESULTS:Our study demonstrated strong inhibitory effects of PTE on GC cells both in vitro and in vivo. In vitro, PTE significantly induced cell cycle arrest at G0/G1 and S phases and suppressed proliferation, migration, and invasion of GC cells. In vivo, PTE led to a dose-dependent reduction in tumor volume and weight. Importantly, PTE exhibited notable safety, leaving mouse weight, liver function, and kidney function unaffected. The involvement of the JAK2/STAT3 pathway in PTE's anti-GC effect was predicted utilizing network pharmacology. PTE suppressed JAK2 kinase activity by binding to the JH1 kinase structural domain and inhibited the downstream STAT3 signaling pathway. Western blotting confirmed PTE's inhibition of the JAK2/STAT3 pathway and EMT-associated protein levels. The anti-GC effect was partially reversed upon STAT3 activation, validating the pivotal role of the JAK2/STAT3 signaling pathway in PTE's activity.CONCLUSION:Our investigation validates the potent inhibitory effects of PTE on the proliferation and metastasis of GC cells. Importantly, we present novel evidence implicating the JAK2/STAT3 pathway as the key mechanism through which PTE exerts its anti-GC activity. These findings not only establish the basis for considering PTE as a promising lead compound for GC therapeutics but also contribute significantly to our comprehension of the intricate molecular mechanisms underlying its exceptional anti-cancer properties.

Mechanism of pterostilbene inhibiting growth of hepatocellular carcinoma by regulating metastasis-associated protein 1 expression

Tumoricidal Activities of Pterostilbene Depend Upon Destabilizing the MTA1-NuRD Complex and Enhancing P53 Acetylation in Hepatocellular Carcinoma

Pterostilbene Inhibits MTA1/HDAC1 Complex Leading to PTEN Acetylation in Hepatocellular Carcinoma.

Pterostilbene Increases PTEN Expression Through the Targeted Downregulation of Microrna-19A in Hepatocellular Carcinoma

Pterostilbene Simultaneously Induces Apoptosis, Cell Cycle Arrest and Cyto-Protective Autophagy in Breast Cancer Cells.

Long Non-coding RNAs Contribute to the Inhibition of Proliferation and EMT by Pterostilbene in Human Breast Cancer

Metallothionein 1H (MT1H) Functions As a Tumor Suppressor in Hepatocellular Carcinoma Through Regulating Wnt/β-catenin Signaling Pathway

Pterostilbene Acts Through Metastasis-Associated Protein 1 To Inhibit Tumor Growth, Progression And Metastasis In Prostate Cancer

Pterostilbene Inhibits Hepatocellular Carcinoma Proliferation and HBV Replication by Targeting Ribonucleotide Reductase M2 Protein.

Up-regulated Expression of Stathmin May Be Associated with Hepatocarcinogenesis.

Mir-106B-5p Promotes Stem Cell-Like Properties of Hepatocellular Carcinoma Cells by Targeting PTEN Via PI3K/Akt Pathway

Pterostilbene upregulates MICA/B via the PI3K/AKT signaling pathway to enhance the capability of natural killer cells to kill cervical cancer cells

Targeting MTA1/HIF-1α signaling by pterostilbene in combination with histone deacetylase inhibitor attenuates prostate cancer progression

Somatostatin Octapeptide Inhibits Cell Invasion and Metastasis in Hepatocellular Carcinoma Through PEBP1

Elucidating the Molecular Mechanisms of Pterostilbene Against Cervical Cancer Through an Integrated Bioinformatics and Network Pharmacology Approach

miR-186-5p Prevents Hepatocellular Carcinoma Progression Through Targeting METTL3 to Regulate m6A-Mediated Stabilization of FSTL5

Pterostilbene Suppresses Gastric Cancer Proliferation and Metastasis by Inhibiting Oncogenic JAK2/STAT3 Signaling: in Vitro and in Vivo Therapeutic Intervention

MiR-186-5p prevents hepatocellular carcinoma progression by targeting methyltransferase-like 3 that regulates m6A-mediated stabilization of follistatin-like 5

Pterostilbene, an Active Constituent of Blueberries, Suppresses Proliferation Potential of Human Cholangiocarcinoma Via Enhancing the Autophagic Flux

Psilostachyin C reduces malignant properties of hepatocellular carcinoma cells by blocking CREBBP-mediated transcription of GATAD2B

Stachydrine inhibits TGF-β1-induced epithelial-mesenchymal transition in hepatocellular carcinoma cells through the TGF-β/Smad and PI3K/Akt/mTOR signaling pathways